Clinical trials in diabetes and CVD: What did we learn?
Expert Meeting on CVD & T2DM10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya
Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.
Video navigation menu
- What do the trial results tell us about CV safety and side-effects of GLP-1 RAs? 0:56
- CV safety and side-effects of SGLT2 inhibitors 2:42
- Efficacy results vary among the trials with the different GLP1 RA agents 4:47
- The observed efficacy results with SGLT2 inhibitors may reflect a class effect 6:48
- GLP-1 RAs and SGLT2 inhibitors seem to positively affect progression of CKD 8:16
- The novel antidiabetic drugs mark a new era in the treatment of T2DM: what does the future look like? 10:00
This video was recorded during a two-day expert meeting among cardiologists and endocrinologists/internists, focussing on the topic of 'Exploring the role of GLP-1 RA in the management of CVD & T2DM'. This video reflects the discussion in the third of five sessions.
Prof. Filippo Crea -cardiologist, Catholic University of the Sacred Heart, Rome, Italy
Prof. Angelyn Bethel - endocrinologist, University of Oxford, United Kingdom
Prof. Eduard Montanya - endocrinologist, University of Barcelona, Spain
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for the Expert Meeting was provided by an unrestricted educational grant from Novo Nordisk. The sponsor did not attend and influence the meeting or the video recording.